Luncheon with Mark Rubin, MD
Topic: "Recent Advances in Cancer Research"
Reception: 11:30 AM
Lunch: Noon
$26 per person
Royal Poinciana Golf Club
1600 Solana Drive
Naples, Florida 34105
Invitation will be mailed in October.
Mark Rubin, MD
Originally from Ontario, Dr. Mark Rubin joined FCS in 1994. He combines more than 15 years of clinical experience with an internationally-recognized track record in cancer research. As a Research Fellow at Memorial Sloan Kettering from 1991 to 1994, Dr. Rubin worked alongside Dr. John Mendelsohn, past President of MD Anderson Cancer Center.
In this role, Dr. Rubin helped to pioneer the concept of targeted anti-receptor therapy as a new form of cancer treatment. Antibody 225, known commercially as Erbitux, was approved by the FDA in 2004 for colon cancer, and in 2006 for head and neck cancer. Dr. Rubin received his BA from Harvard University, and his M.D. from the College of Physicians and Surgeons at Columbia University in New York City. He completed his Internship and Residency in Internal Medicine at UCLA Medical Center. His work has been widely published in such prestigious publications as the Journal of Cell Physiology and the American Journal of Clinical Oncology. Dr. Rubin has been principal investigator or sub-investigator on nearly 100 clinical research trials, and is a sought-after national and international lecturer. He is consistently named one of the top doctors in Southwest Florida by Castle Connolly America’s Top Doctors.
As a child, Dr. Rubin dreamed of becoming President of the United States (even though he was Canadian.) Today, he counts becoming an American citizen as one of his proudest moments. Dr. Rubin and his wife, Anne, are the parents of twins Charles and Caroline. In his free time, he enjoys skiing, sailing, traveling and showing the world to his family.